

Overview of CML related sessions at 23rd EHA Meeting in Stockholm

Time slots	Sessions	Location
June 14th (Thursday)		
8.00 – 10.00	<p>Satellite Symposium: Targeting the individual: Personalized treatment in CML (Supported by Pfizer Oncology)</p> <p>Chair:</p> <ul style="list-style-type: none"> • Prof. R Clark (Royal Liverpool University Hospital, UK) <p>Program:</p> <ul style="list-style-type: none"> • Introduction (R Clark) • A new option in the treatment of first-line CML (M Deininger) • A wealth of choices in first-line CML: how to choose the right TKI in first line (R Clark) • Treatment options in second-line and beyond: A case-based discussion (D Wolf) • Chronic treatment vs. cure: future challenges in CML treatment (H Hjort-Hansen) • Q&A (R. Clark) 	Room A2
10.45 – 12.45	<p>Satellite Symposium: Recent advances in CML and MPN's (Supported by Novartis Oncology)</p> <p>Chairs:</p> <ul style="list-style-type: none"> • Prof. A Hochhaus (University Hospital Jena, Germany) • Dr J Samuelsson (Stockholm South Hospital, Sweden) <p>Program:</p> <ul style="list-style-type: none"> • Welcome (S. Samuelsson) 	Room A1

Time slots	Sessions	Location
	<ul style="list-style-type: none"> Current treatment landscape in CML (TP Hughes) Current treatment landscape in classical MPN (RA Mesa) Challenges and future perspectives in CML (JE Cortes) Challenges and future perspectives in classical MPN's (AM Vannucchi) Summary and Q&A (A Hochhaus) 	
10.45 – 12.45	<p>Satellite Symposium: Immuno-oncology in haematologic malignancies: The evolving biomarker story (Supported by Bristol Myers Squibb)</p> <p>Chair: Dr O Landgren (Memorial Sloan Kettering Cancer Center, New York, USA)</p> <p>Program:</p> <ul style="list-style-type: none"> Insights and current perspectives: An Introduction to I-O advances and biomarker research (O. Landgren) Gaining an understanding of the relationship between the tumor and the tumor microenvironment (B Paiva) The individualized approach: Personalizing medicine through biomarkers (A Diepstra) Evolving bench to bedside and back: Designing biology-driven studies (N Daver) 	Room A2
June 15th (Friday)		
14.30 – 15.30	<p>Meet-the-expert: Treatment options in resistant CML patients</p> <p>Speaker: Prof. J Apperley</p>	Room A12
June 16th (Saturday)		
8.00 – 9.30	<p>Patient Advocacy Session 1: QoL – Why still an inconsistent path to an obvious goal?</p> <p>Chairs:</p>	Room K21

Time slots	Sessions	Location
	<ul style="list-style-type: none"> • L Brunetta (Thalassaemia International Federation, Genoa, Italy) • S Wintrich (MDS UK Patient Support Group, London, UK) <p>Program:</p> <ul style="list-style-type: none"> • Introduction: Is quality of life a priority in treatment today? A patient perspective (A Bok) • Quality of life during and after treatment (H Kaur) • Treatment at home for haematological patients: Safe, feasible – and improving patient experience? (L Kjelden) • The impact of cancer and its treatment on sex life (A Plate) • From frail to fit: The importance of pre-rehabilitation and rehabilitation on QoL (N Bolaños) 	
9.45 – 10.45	<p>Scientific Working Group (SWG): Chronic myeloid leukemia – ELN-EHA SWG session on CML 2018</p> <p>Chair:</p> <ul style="list-style-type: none"> • Prof. R Hehlmann (ELN Foundation, Weinheim, Germany) <p>Program:</p> <ul style="list-style-type: none"> • The relevance of cytogenetics in the course of CML (C Haferlach) • Does IFN improve outcome of CML in the imatinib era? (FE Nicolini) • Worldwide standardization of BCR-ABL monitoring (N Cross) • End results of the EUTOS-registry project (M Baccarani) 	Room A8
11.30 – 12.45	<p>Patient Advocacy Session 2: Not only survival: Patient-reported endpoints and patient-reported outcomes</p>	Room K21

Time slots	Sessions	Location
	<p>Chairs:</p> <ul style="list-style-type: none"> J Geissler (CML Advocates Network, Munich, Germany) M Piggin (PNH Support, London, UK) <p>Program:</p> <ul style="list-style-type: none"> Are study endpoints like OS and PFS most relevant to patients and describe highest patient value? (J Geissler) Meaningful patient-reported outcomes – How to learn from real-life experience in clinical research (G Garcia-Manero) The end of huge questionnaires? Innovative electronic PRO measurement tools (H Kaur) Q&A panel discussion (J Geissler, G Garcia-Manero, H Kaur) 	
14.45 – 15.45	<p>Advocacy Session: EU projects in hematology: HARMONY: Big data and big data analytics: To enable better and faster treatment for patients with hematologic malignancies</p> <p>Chair: JM Hernández</p> <p>Program:</p> <ul style="list-style-type: none"> Welcome and introduction (P Sonneveld) HARMONY: First year achievements (G Sanz & P Bacon) Data management and analytics of the HARMONY data platform (M van Speybroeck & R Villoria) Legal aspects of data protection in HARMONY (J Butler) HARMONY: Unlocking valuable knowledge: Overview of “Bench-to-bedside” Pilot projects (L Bulling & A Taylor) AML: Leading the way: the first results (H Döhner & S Mendelson) Update of the MM ad APL projects (P Ghia) 	Room K2

Time slots	Sessions	Location
	<ul style="list-style-type: none"> Wrap up & Invitation to become a data provider (JM Hernández) 	
16.00 – 17.15	<p>EHA Advocacy Session: The real-world value of new generation treatments</p> <p>Chair: O Ottoman (Cardiff University, UK)</p> <p>Program:</p> <ul style="list-style-type: none"> What does the real world look like? The patient perspective (M Piggin) The use of patient reported outcome measures (PROMs) to drive patient interests: an ICHOM perspective (M Ingvar) Good decisions need good data: an HTA perspective (S Lange) 	Room K21
17.30 – 19.00	<p>Update in Hematology: Biosimilars in Hematology – Plotting the course to long-term sustainability (Supported by Sandoz)</p> <p>Chair:</p> <ul style="list-style-type: none"> Dr PC Cornes (Comparative Outcomes Group, Bristol, UK) <p>Program:</p> <ul style="list-style-type: none"> Introduction and welcome (PC Cornes) A patient's journey: A life without biosimilars (S Scowcroft) Why we need biosimilars: Mapping out a path to sustainable care (P Cornes) A patient's journey: A life with biosimilars (S Scowcroft) Panel speaks: Navigating the totality of evidence for rituximab biosimilars: how much and which data are necessary? (AG Vulto) A patient's journey: Does extrapolation matter? (S Scowcroft) Panel speaks: Driving data extrapolation in hematologic malignancies: Key considerations for clinical practice (C Buske) Ask the faculty and closing remarks (P Cornes) 	Room A7

Time slots	Sessions	Location
June 17th (Sunday)		
9.30 – 11.00	Education Session: Chronic myeloid leukemia Chair: Prof. S. Sauße (Universitätsklinikum Mannheim, Germany) Program: <ul style="list-style-type: none"> • Single cell genomics in CML (A Mead) • Immune targeting of CML to improve treatment outcome (A Burchert) • TFR treatment goal for all CML patients (D Rea) 	Room K1
11.15 – 12.45	Education Session: Chronic myeloid leukemia Chair: Prof. S. Sauße (Universitätsklinikum Mannheim, Germany) Program: <ul style="list-style-type: none"> • Single cell genomics in CML (A Mead) • Immune targeting of CML to improve treatment outcome (A Burchert) • TFR treatment goal for all CML patients (D Rea) 	Room K1